4105 Stock Overview
Engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
TTY Biopharm Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$74.80 |
| 52 Week High | NT$87.00 |
| 52 Week Low | NT$74.50 |
| Beta | 0.21 |
| 11 Month Change | -2.22% |
| 3 Month Change | -2.35% |
| 1 Year Change | -2.86% |
| 33 Year Change | -6.97% |
| 5 Year Change | -6.03% |
| Change since IPO | 1,136.21% |
Recent News & Updates
Recent updates
Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly
Apr 02
Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?
Mar 15Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?
Feb 25TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Feb 07TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially
Jan 19What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 10
TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet
Dec 15How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?
Nov 25Shareholder Returns
| 4105 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.9% | -1.8% | -2.3% |
| 1Y | -2.9% | 13.6% | 31.2% |
Return vs Industry: 4105 underperformed the TW Pharmaceuticals industry which returned 13.6% over the past year.
Return vs Market: 4105 underperformed the TW Market which returned 31.2% over the past year.
Price Volatility
| 4105 volatility | |
|---|---|
| 4105 Average Weekly Movement | 1.2% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.5% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 4105 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4105's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | n/a | n/a | www.tty.com.tw |
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments.
TTY Biopharm Company Limited Fundamentals Summary
| 4105 fundamental statistics | |
|---|---|
| Market cap | NT$18.60b |
| Earnings (TTM) | NT$1.17b |
| Revenue (TTM) | NT$5.61b |
15.9x
P/E Ratio3.3x
P/S RatioIs 4105 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4105 income statement (TTM) | |
|---|---|
| Revenue | NT$5.61b |
| Cost of Revenue | NT$2.26b |
| Gross Profit | NT$3.35b |
| Other Expenses | NT$2.18b |
| Earnings | NT$1.17b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.71 |
| Gross Margin | 59.68% |
| Net Profit Margin | 20.86% |
| Debt/Equity Ratio | 27.0% |
How did 4105 perform over the long term?
See historical performance and comparison